The Effects of Exenatide on Post-Meal Sugar Peaks and Vascular Health in Obese/Pre-Diabetic Young Adults

NCT00845559 on ClinicalTrials.gov · last registry update 2012-12-11

Withdrawn before anyone was enrolled. Its estimated completion date, March 2010, has passed with no update to the record. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. exenatide is approved in the US, but not for cardiovascular disease and obesity — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: WITHDRAWN
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: Yale University
Sponsor type: Other
Enrollment: 0
Started: 2008-08
Primary completion: 2010-03 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Whether treatment with exenatide attenuates post-prandial glycemic excursions as assessed by oral glucose tolerance testing (OGTT) and continuous monitoring system (CGMS) technology.

Conditions studied

Obesity · Insulin Resistance · Impaired Glucose Tolerance · Cardiovascular Disease

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.